GlassScriptPhysician profile
John J Villa
NPI 1144309147
$15,425.62
in general payments reported to CMS, 2019-2025
40 companies · $4,351 in 2025
The $4,351 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $905 · 2021: $646 · 2022: $1,155 · 2023: $2,485 · 2024: $3,737 · 2025: $4,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $454 · Consulting Fee: $57.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,061.18 |
| Education | $454.28 |
| Consulting Fee | $57.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,871.66 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $2,726.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,324.41 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $693.74 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $662.39 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $617.16 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $616.43 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $535.91 | 2019-2025 | |
| Inspire Medical Systems, INC. | $503.97 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $427.85 | 2019-2025 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $374.43 | 2023-2025 | Wakix |
| Verona Pharma, INC. | $363.51 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $321.57 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $276.94 | 2025 | Yupelri |
| Pulmonx Corporation | $267.00 | 2020-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $265.56 | 2023-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $255.85 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $226.78 | 2019-2020 | |
| Philips North America LLC | $216.44 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $213.99 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $192.07 | 2019-2024 | Keytruda, Winrevair |
| Genentech USA, INC. | $185.20 | 2019-2023 | Xolair |
| Ani Pharmaceuticals, INC. | $172.86 | 2022-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $167.98 | 2024-2025 | |
| United Therapeutics Corporation | $155.61 | 2019-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $137.94 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $120.93 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.89 | 2020-2025 | Glassia, Aralast |
| Bayer Healthcare Pharmaceuticals INC. | $67.10 | 2021-2025 | |
| Adma Biomanufacturing LLC | $57.28 | 2025 | |
| Pfizer INC. | $54.36 | 2019-2025 | |
| Baxter Healthcare | $54.21 | 2023 | Hillrom - Life 2000 Ventilation System |
| Shire North American Group INC | $40.97 | 2019 | |
| Lilly USA, LLC | $40.11 | 2023-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $27.16 | 2019-2020 | |
| Axsome Therapeutics, INC. | $16.81 | 2023 | Sunosi |
| Vifor Pharma, INC. | $15.45 | 2025 | Zemaira |
| Mallinckrodt Enterprises LLC | $14.93 | 2019 | |
| Covis Pharma Gmbh | $14.90 | 2022 | |
| Optinose US, INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.